Meeting
2015 ASCO Annual Meeting
A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Authors
Ji-Youn Han
National Cancer Center, Goyang, South Korea
Ji-Youn Han , Jin Soo Lee , Ki Hyeong Lee , Sang-We Kim , Young Joo Min , Eun Kyung Cho , Young Joo Lee , Soo-Hyun Lee , Hyae Young Kim , Geon Kook Lee , Byung-Ho Nam , Jong Hee Han , Jung Yong Kim , Jina Jung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01718847
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8085)
DOI
10.1200/jco.2015.33.15_suppl.8085
Abstract #
8085
Poster Bd #
409
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.
First Author: Zandong Yang
Poster
2023 ASCO Annual Meeting
Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).
First Author: Min Hee Hong
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2021 ASCO Annual Meeting
Activity of erlotinib in patients (pts) with advanced chordoma: A retrospective study.
First Author: Olivier Mir